Skip to main content

Table 2 Characteristics of the complying and non-complying groups

From: Pharmacoeconomic effect of compliance with pharmacist’s intervention based on cancer chemotherapy regimens: a cohort study

 

Total n = 96

Complying group n = 58

Non-complying group n = 38

P value

Age (years)

68.6 ± 10.8

68.2 ± 10.2

69.3 ± 11.7

0.6271)

Male/female

44/52

27/31

17/21

0.9992)

History of chemotherapy (yes/no)

25/71

17/41

8/30

0.4772)

ECOG PS (0-1/2)

93/3

57/1

36/2

0.5602)

Adjuvant chemotherapy (yes/no)

7/92

6/52

1/37

0.2382)

Clinical department (number, %)

    

 Surgery

25 (26.0)

18 (31.0)

7 (18.4)

 

 Hematology

31 (32.3)

6 (10.3)

25 (65.8)

 

 Respiratory medicine

19 (19.8)

19 (32.8)

0 (0.0)

 

 Gastroenterology

11 (11.5)

7 (12.1)

4 (10.5)

0.0983)

 Gynecology

4 (4.2)

4 (6.9)

0 (0.0)

 

 Urology

5 (5.2)

4 (6.9)

1 (2.6)

 

 Dental surgery

1 (1.0)

0 (0.0)

1 (2.6)

 

Neutrophil count (/mL)

730±245

746±286

708±240

0.371)

  1. Data are expressed as the mean SD or number (%).1)unpaired t-test, 2)Fisher’s exact test, 3)Mann–Whitney test. ECOG PS, Eastern Cooperative Oncology Group performance status. G-CSF, Granulocyte colony-stimulating factor.